Show simple item record

dc.contributor.authorNixon, J
dc.contributor.authorSmith, I
dc.contributor.authorBrown, S
dc.contributor.authorMcGinnis, E
dc.contributor.authorVargas-Palacios, A
dc.contributor.authorNelson, EA
dc.contributor.authorColeman, S
dc.contributor.authorCollier, H
dc.contributor.authorFernandez, C
dc.contributor.authorGilberts, R
dc.contributor.authorHenderson, V
dc.contributor.authorMuir, D
dc.contributor.authorStubbs, N
dc.contributor.authorWalker, K
dc.contributor.authorWilson, L
dc.contributor.authorHulme, C
dc.date.accessioned2019-08-08T12:46:11Z
dc.date.issued2019-09-03
dc.description.abstractBackground Pressure ulcers (PUs) are complications of serious acute/chronic illness. Specialist mattresses used for prevention lack high quality effectiveness evidence. We aimed to compare clinical and cost effectiveness of 2 mattress types. Methods Multicentre, Phase III, open, prospective, parallel group, randomised, controlled trial in 42 UK secondary/community in-patient facilities. 2029 high risk (acutely ill, bedfast/chairfast and/or Category 1 PU/pain at PU site) adult inpatients were randomised (1:1, allocation concealment, minimisation with random element) factors including: centre, PU status, facility and consent type. Interventions were alternating pressure mattresses (APMs) or high specification foam (HSF) for maximum treatment phase 60 days. Primary outcome was time to development of new PU Category≥2 from randomisation to 30 day post-treatment follow-up in intention-to treat population. Trial registration: ISRCTN 01151335 Findings: Between August 2013 and November 2016, we randomised 2029 patients (1016 APMs: 1013 HSF) who developed 160(7.9%) PUs. There was insufficient evidence of a difference between groups for time to new PU Category≥2 Fine and Gray Model Hazard Ratio HR=0.76, 95%CI0.56-1.04); exact P=0.0890; absolute difference 2%). There was a statistically significant difference in the treatment phase time to event sensitivity analysis, Fine and Gray model HR=0.66, 95%CI, 0.46-0.93; exact P=0.0176); 2.6% absolute difference). Economic analyses indicates that APM are cost-effective. There were no safety concerns. Interpretation: In high risk (acutely ill, bedfast/chairfast/Category 1 PU/ pain on a PU site) in-patients, we found insufficient evidence of a difference in time to PU development at 30-day final followup, which may be related to a low event rate affecting trial power. APMs conferred a small treatment phase benefit. Patient preference, low PU incidence and small group differences suggests the need for improved targeting of APMs with decision making informed by patient preference/comfort/rehabilitation needs and the presence of potentially modifiable risk factors such as being completely immobile, nutritional deficits, lacking capacity and/or altered skin/Category1 PU.en_GB
dc.description.sponsorshipNational Institute for Health Research (NIHR)en_GB
dc.identifier.citationPublished online 3 September 2019en_GB
dc.identifier.doi10.1016/j.eclinm.2019.07.018
dc.identifier.urihttp://hdl.handle.net/10871/38282
dc.language.isoenen_GB
dc.publisherElsevieren_GB
dc.rights© 2019 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http:// creativecommons.org/licenses/by-nc-nd/4.0/). en_GB
dc.titlePressure relieving support surfaces for pressure ulcer prevention (PRESSURE 2): clinical and health economic results of a randomised controlled trialen_GB
dc.typeArticleen_GB
dc.date.available2019-08-08T12:46:11Z
dc.identifier.issn0140-6736
dc.descriptionThis is the final version. Available on open access from Elsevier via the DOI in this recorden_GB
dc.descriptionData Sharing Statement: The datasets during and/or analysed during the current study will be available from the corresponding author on reasonable request.en_GB
dc.identifier.eissn1474-547X
dc.identifier.journalLanceten_GB
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/  en_GB
dcterms.dateAccepted2019-07-01
rioxxterms.versionVoRen_GB
rioxxterms.licenseref.startdate2019-07-01
rioxxterms.typeJournal Article/Reviewen_GB
refterms.dateFCD2019-08-08T12:44:24Z
refterms.versionFCDAM
refterms.dateFOA2019-09-11T14:42:38Z
refterms.panelAen_GB


Files in this item

This item appears in the following Collection(s)

Show simple item record

© 2019 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/). 
Except where otherwise noted, this item's licence is described as © 2019 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http:// creativecommons.org/licenses/by-nc-nd/4.0/).